Search Results
Oct 14, 2025, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for Boehringer Ingelheim's JASCAYD® (nerandomilast)
About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Oct 14, 2025, 07:55 ET Akadeum Life Sciences and BioIVT Collaborate to Provide Robust Starting Material to Developers of Cell Therapy Products
specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. By combining technical expertise and exceptional customer service with unmatched access to biological
More news about: Akadeum Life Sciences
Oct 14, 2025, 07:13 ET Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Brogidirsen is an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP as an investigational therapy for DMD patients with dystrophin gene mutations that are amenable to exon 44 skipping. "These long-term motor function data suggest the potential for brogidirsen to
More news about: NS Pharma, Inc.
Oct 14, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
lung cancer patients, which shares in sponsoring this preclinical study. TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex®
More news about: Genprex, Inc.
Oct 14, 2025, 03:30 ET First patient treated with Leqembi® (lecanemab) in the Nordics
involved in the metabolism of lipid in humans. It is implicated in AD. People with only one (heterozygous) or no copy (non-carriers) of the ApoE ε4 gene are less likely to experience ARIA than people with two ApoE ε4 copies (homozygous).ii ARIA is a recognized important side effect with lecanemab
More news about: BioArctic
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 11:20 ET Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by Advancements in Targeted Therapies and Drug Delivery Innovations | According DataM Intelligence
the forecast period 2025-2033, driven by rising chronic diseases, demand for targeted therapies, and advancements in drug delivery, mRNA vaccines, and gene editing.
More news about: DataM Intelligence 4 Market Research LLP
Oct 13, 2025, 09:00 ET Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG
Wittner, president of Gene by Gene. Having already processed more than 40,000 genomes using Complete Genomics' DNBSEQ technology, Gene by Gene is performing a wide
More news about: Complete Genomics
Oct 13, 2025, 09:00 ET Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
designation, is an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy who have gene mutations amenable to exon 44 skipping (DMD44).
More news about: Avidity Biosciences, Inc.
Oct 13, 2025, 08:43 ET AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion
support precision multi-omic testing for the United States market soon. The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC)
More news about: AccuGenomics
Oct 13, 2025, 08:30 ET Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, for which Actinium is seeking a
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2
More news about: Waters Corporation
Oct 13, 2025, 08:05 ET Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2
More news about: Waters Corporation
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
inhibitor designed to selectively target tumors with PIK3CA mutations while sparing wild-type PI3Kα. Activating mutations in the PIK3CA gene (which encodes PI3Kα enzyme) are oncogenic drivers present in approximately 40% of hormone receptor positive (HR+)/HER2-negative breast cancers and
More news about: Eli Lilly and Company
Oct 10, 2025, 08:02 ET Weekly Recap: 13 Health Press Releases You Need to See
GEMMABio Launches Rare Therapeutics, Inc. to Develop and Deliver Gene Therapies for Ultra–Orphan Diseases This new clinical-stage company will accelerate treatments
More news about: PR Newswire
Oct 09, 2025, 12:17 ET RegCell Scientific Founder and Board Member Dr. Shimon Sakaguchi Awarded Nobel Prize in Physiology or Medicine
gene governs their development. "We are deeply honored to count on Dr. Sakaguchi as a scientific founder of RegCell and among
More news about: RegCell, Inc.
Oct 09, 2025, 11:10 ET Endoscopy Procedures Market to Reach $617.8 billion, Globally, by 2034 at 5.5% CAGR: Allied Market Research
Gene Therapy Market: Global Opportunity Analysis and Industry Forecast, 2023-2032
More news about: Allied Market Research
Oct 09, 2025, 11:05 ET Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery
Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du as a spin-out from Nobel laureate Jennifer Doudna's lab at UC Berkeley,
More news about: LifeSpan Vision Ventures
Oct 09, 2025, 11:05 ET Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery
Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du as a spin-out from Nobel laureate Jennifer Doudna's lab at UC Berkeley,
More news about: LifeSpan Vision Ventures
Oct 09, 2025, 10:10 ET Wearable Medical Devices Market Poised for USD 499.2 Billion by 2035, Growing at a CAGR 21.6% | Strategic Insights for CXOs and Healthcare Leaders
https://www.vantagemarketresearch.com/industry-report/mhealth-market-2204 Gene Editing Market is valued at USD 9.3 Billion in 2024 and is projected to reach a value of USD 46.62 Billion by 2035 at a CAGR (Compound Annual Growth
More news about: Vantage Market Research
Oct 09, 2025, 09:33 ET Health-E Commerce® Collaborates with Curex® to Deliver At-Home Allergy Relief for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users
helped more than 50 thousand people find long-term relief from allergy symptoms that can disrupt daily activities and diminish quality of life," said Gene Kakaulin, founder and CEO, Curex. "The ability to access allergy care at home and to save money by purchasing our services with their FSA and HSA funds
More news about: Health-E Commerce
Oct 09, 2025, 09:03 ET Aeston West Launches in Beauty Market Offering a Duality by Design Principle
formulated to work deeper within the skin's layers to support its natural renewal engine and help maintain a healthier look and feel. In an in-vitro gene study, 1% Cellevitae™ was shown to significantly boost the expression of two key skin health markers -vascular endothelial growth factor (VEGF), associated
More news about: Aeston West
Oct 09, 2025, 08:30 ET Pediatric Hematology-Oncology Trials: Successful Novel Therapeutic Strategies, Upcoming Webinar Hosted by Xtalks
treatments are available remains a major obstacle. This webinar addresses these key challenges in advanced therapies, including gene and cellular therapies, while offering different and innovative approaches that can be put into practice so that future clinical trials can avoid enrollment
More news about: Xtalks
Oct 09, 2025, 07:05 ET REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Oct 09, 2025, 06:00 ET Allelica Launches AbsoluteDx: The Most Comprehensive Genetic Risk Assessment, Combining Monogenic and Polygenic Insights Across Multiple Diseases
carry the same monogenic mutation (like those in the CHEK2 gene for breast cancer) but have very different absolute risk levels because their breast cancer PRS modulates the penetrance of the mutations in the CHEK2 gene. As such, these patients need to be treated differently. Absolute Dx
More news about: Allelica, Inc.